Advanced gastric cancer

Researchers are testing whether adding an experimental drug called 2141-V11 to standard immunotherapy is safe for people with advanced esophageal, gastric, or gastroesophageal junction adenocarcinoma. Participants receive injections of 2141-V11 directly into their tumors along wi…

This Phase 2 trial tests whether adding an extra drug (either SHR2554 or apatinib) to standard immunotherapy plus chemotherapy can help people with advanced gastric cancer who don't get enough benefit from current treatments. About 78 adults with stage III or IV stomach cancer wi…

This study tests a new drug, BHB810, in adults with advanced stomach or gastroesophageal junction cancer that has not responded to standard treatments. The drug is given as an IV infusion every two weeks. The main goals are to check safety and find the best dose, while also seein…

This study tests whether a 3-day low-leucine diet can make chemotherapy and immunotherapy work better for people with advanced stomach cancer. Researchers believe the diet may activate immune cells in the tumor. The trial involves 73 participants and will measure tumor shrinkage …

This early-stage trial tests a new treatment for advanced gastric cancer that has not responded to standard therapies. It combines a special vaccine made from the patient's own tumor markers (neoantigens) with immune cells trained to attack the cancer. The main goals are to see i…

This study tests a new combination of drugs for people with advanced stomach cancer that got worse after initial immunotherapy. The treatment includes a targeted therapy (fruquintinib), chemotherapy (nab-paclitaxel), and a new immunotherapy (iparomlimab and tuvonralimab). The goa…

This study tests a new combination of two experimental drugs (iparomlimab and tuvonralimab, together called QL1706) plus standard chemotherapy in people with advanced stomach or gastroesophageal junction cancer that hasn't been treated before. The goal is to see if this combo can…

This study tests a new drug called LM-108, which clears certain immune cells from tumors, combined with standard chemotherapy and another immunotherapy. The goal is to see if this mix is safe and can slow or shrink advanced solid tumors. About 194 adults with advanced cancers wil…

This Phase 2 trial is testing whether a new targeted drug called SHR2554, taken as a tablet, can be safely combined with other anti-cancer injections to treat advanced stomach or gastroesophageal junction cancer. The study will enroll 351 adults whose cancer has spread or cannot …

This study tests a combination of two drugs—glumetinib (a targeted therapy) and a special form of docetaxel (chemotherapy)—in people with advanced stomach cancer or other solid tumors that have a specific genetic marker called MET overexpression. The trial has two stages: first t…

Researchers at Ruijin Hospital are testing two PET imaging tracers, FAPI and Grazytracer, to see if they can predict how well advanced gastric cancer responds to preoperative immunotherapy. The study enrolls 120 adults with resectable or advanced gastric cancer. Participants rece…

This study tests whether a smartphone app that lets cancer patients report their symptoms, combined with regular calls from a specially trained nurse, can help them better manage chemotherapy side effects and improve their quality of life. The study includes 414 adults with early…

This study looks at how well certain markers in tumors can predict whether a type of targeted cancer treatment called antibody-drug conjugates (ADCs) will work. About 400 adults with advanced breast, stomach, bladder, or lung cancer will provide tumor samples before and after tre…